Navidea Biopharmaceuticals, Inc.
NAVB
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -99.48% | -96.03% | -83.91% | -87.66% | -83.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.48% | -96.03% | -83.91% | -87.66% | -83.54% |
| Cost of Revenue | -62.94% | 36,780.00% | -- | -- | -- |
| Gross Profit | -153.33% | -186.51% | -129.24% | -122.43% | -102.78% |
| SG&A Expenses | -20.27% | -29.21% | -31.95% | -28.06% | -7.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.51% | -13.76% | -8.83% | -8.56% | 0.31% |
| Operating Income | 13.68% | 12.35% | 6.21% | 5.08% | -5.55% |
| Income Before Tax | 43.91% | 0.01% | -16.45% | -29.55% | -40.98% |
| Income Tax Expenses | -- | -- | -- | -- | -100.00% |
| Earnings from Continuing Operations | 43.91% | 0.14% | -16.30% | -29.38% | -40.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 92.30% | 61.62% | -16.30% | -29.38% | -40.77% |
| EBIT | 13.68% | 12.35% | 6.21% | 5.08% | -5.55% |
| EBITDA | 13.93% | 12.62% | 6.41% | 5.27% | -5.44% |
| EPS Basic | 90.40% | 28.98% | -28.32% | -39.57% | -46.14% |
| Normalized Basic EPS | 47.28% | 32.78% | 20.69% | 12.16% | -0.28% |
| EPS Diluted | 90.40% | 28.98% | -28.32% | -39.57% | -46.14% |
| Normalized Diluted EPS | 47.28% | 32.78% | 20.69% | 12.16% | -0.28% |
| Average Basic Shares Outstanding | 75.20% | 19.25% | 5.37% | 5.21% | 6.44% |
| Average Diluted Shares Outstanding | 75.20% | 19.25% | 5.37% | 5.21% | 6.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
